Steady Expansion Forecast for Adalimumab, Infliximab and Etanercept Biosimilars Market, Projected to Reach $7.34 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Adalimumab, Infliximab and Etanercept Biosimilars Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for biosimilars of adalimumab, infliximab and etanercept has experienced fast-paced growth in the last few years. Forecasts predict an increase from $4.37 billion in 2024 to $4.96 billion in 2025, with a compound annual growth rate (CAGR) of 13.6%. Factors leading to the growth during the historical timeframe include higher healthcare spending, changes in regulations, government measures, and escalating healthcare expenses.

Adalimumab, Infliximab and Etanercept Biosimilars Market Size Forecast: What's the Projected Valuation by 2029?
Expect a swift escalation in the market size of adalimumab, infliximab, and etanercept biosimilars in the subsequent years. The market is projected to expand to "$7.34 billion in 2029 with a compound annual growth rate (CAGR) of 10.3%. The propulsion during the forecast period is ascribed to elevating healthcare spending, an expanding elderly population, and increased healthcare access that accelerates market growth. Leading tendencies during the forecast period encompass attention on the introduction of new products, emphasis on mergers and buyouts, a concentration on forming strategic alliances, and a focus on inflating investments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

What Are the Drivers Transforming the Adalimumab, Infliximab and Etanercept Biosimilars Market?
Biosimilars are able to infiltrate the adalimumab, infliximab, and etanercept biosimilars market due to the patent termination of branded pharmaceuticals. For example, in America, following the end of Remicade's patent, the FDA gave the green light to Inflectra, a drug created by Hospira (a subsidiary of Pfizer Inc.), for treating several autoimmune disorders including rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. In a similar vein, after the patent of Amgen's Enbrel expired in the EU, the European Commission gave approval to Benepali, a biosimilar of Enbrel. Following the patent termination of Humira, its biosimilars were introduced to the market, and recently, the FDA authorized Hulio, Humira's sixth biosimilar. Consequently, the end of patents for branded biologic drugs like Humira, Enbrel, and Remicade will push the adalimumab, infliximab, and etanercept biosimilars market forward.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

What Trends Will Shape the Adalimumab, Infliximab and Etanercept Biosimilars Market Through 2029 and Beyond?
Leading businesses in the adalimumab, infliximab, and etanercept biosimilars market are concentrating their efforts on creating novel products like citrate-free adalimumab to offer dependable services to their clients. This is a variant of the biological drug adalimumab that lacks citrate. For instance, Fresenius Kabi, a medical and technological solutions provider from Germany, revealed in December 2022, that the FDA has given its nod for the biosimilar Idacio (adalimumab) for treating chronic autoimmune diseases. This asset, designed for all the permissible usages of the reference product, leverages refined analytical methods to aid in the management of numerous chronic ailments.

Which Segments in the Adalimumab, Infliximab and Etanercept Biosimilars Market Offer the Most Profit Potential?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented -

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

Which Firms Dominate the Adalimumab, Infliximab and Etanercept Biosimilars Market by Market Share and Revenue in 2025?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

Which Regions Offer the Highest Growth Potential in the Adalimumab, Infliximab and Etanercept Biosimilars Market?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3473

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email:saumyas@tbrc.info
The Business Research Company -www.thebusinessresearchcompany.com
Follow Us On:
LinkedIn:https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.